# Ultrasound transducer disinfection for percutaneous procedures.


---Invasive devices session--



ACIPC Adelaide 2023

#### **Dr Nathan Peters**

Senior Staff Specialist Anaesthetist RBWH, QLD



# Acknowledgements

- ASUM Research Grant Funding
- No conflicts of interest
- Co-authors:

F Williamson, P Snelling, M Bauer, P Harris, A Stewart, S Llewellyn, N Marsh, C Rickard




### **USG** percutaneous procedures

- Vascular access
- Nerve blocks
- Injections
- Biopsy
- Aspirations
- Drainage



Ultrasound =  $\uparrow$  Success and  $\downarrow$  Complications



Should US transducers used in percutaneous procedures undergo **Low-level** or **High-level** disinfection?



Region	Society	HLD	LLD
Australia	ASUM/ACIPC	✓	
	CICM	$\checkmark$	
	ACEM		$\checkmark$
	ANZCA		$\checkmark$
America	AIUM		$\checkmark$
Europe	ESR	$\checkmark$	
World	WFUMB	<b>✓</b>	

### LLD

#### **LOW-LEVEL DISINFECTION**

### HLD

#### **HIGH-LEVEL DISINFECTION**





~\$0.10

- Benzalkonium Cl
- PMH Biguanide




~\$13.00

~\$10,000+

Cl dioxide; H<sub>2</sub>O<sub>2</sub>; UV-C light

#### Effectiveness of different levels of disinfection



# Why is this important?

	Low-level	High-level	<u>Costs:</u>
Training & annual competency	No	Yes	↓US Availability ↑Staff time ↑Money
Perform easily at bedside	Yes	No	
Traceability log & audit	No	Yes	·
Cost	\$0.10	\$13	

Would HLD deliver any benefit?... well let's find out...

## Hypothesis....

#### Microorganisms from skin:

- 1. Contaminate US transducers;
- 2. May cause infection;
- 3. LLD & HLD theoretically effective.

#### LLD should be non-inferior to HLD for skin microbes

### **Design - outcome**

Elimination of all viable microorganisms from US transducers after LLD or HLD. (CFUs=0)

- 2 identical linear US transducers
  - LLD transducer -> only LLD
  - HLD transducer -> only HLD

Randomised to L or R arm

- Patients and Healthcare staff
  - HREC approval
  - Exclusion criteria
  - Contamination simulated on forearms + 10g sterile gel



# Design - sample analysis

- Contamination → Swab → Disinfection → Swab
  - LLD Clinell universal wipes®
  - HLD Tristel Trio wipes®
- Blinding of microbiologist
- Swabs plated on Horse Blood Agar plates
  - supports growth of aerobic bacteria & fungi
- Incubated in air at 37°c for 4 to 5 days
- CFU counted and identified





### **Design – Statistics & Power**

- Non-inferiority trial
  - paired statistical testing using Nam's restricted maximum likelihood estimate (RMLE) approach
  - -5% non-inferiority margin & 2.5% significance level
- Power = 470 participants with paired microbial growth
  - 650 recruited to account for no growth samples
- Prospective registration ANZCTR


### Results

### 654 participants:

- 76% (n=495) patients, 24% (n=157) staff
- 53% (n= 345) male, 47% (n= 309) female



- 73% (n=478) Both
- 13% (n= 82) One
- 14% (n=94) None



#### Top 3: (n=1669)

- 1. Coag. neg Staph (51%)
- 2. Micrococcus luteus (29%)
- 3. Staph aureus (8%)

### Results


• 478 paired growth

#### All CFUs eliminated:

- HLD: 100% (99.4%-100.0%) (n=478)
- LLD: 99.0% (97.6%-99.7%) (n=473)

(5 with 1-2 CFUs remaining (CoNS or M.Luteus))

#### Non-inferiority plot



# Limitations & generalizability


- Simulated contamination
- Unprepared skin & no transducer covers
- No blood present (Occasional, Cleaning, Covers, Sens. BBV)
- One brand of LLD and HLD
- Infection rate not a faesible outcome

# **Summary & Implications**

### LLD is non-inferior to HLD

- 1. Infection risk from transducer treated with LLD would be no higher than HLD.
- 2. Widespread real benefits to patients, staff & organisations.
- 3. Strong evidence for guidelines to adopt LLD as standard.

So, what next....







Original Article 🖸 Open Access 🚾 📵 🥞

Comparison of Low-Level to High-Level Disinfection in Eliminating Microorganisms From Ultrasound Transducers Used on Skin

A Noninferiority Randomized Controlled Trial

Nathan Peters BPharm, MBBS, FANZCA, PGDipClinUS ⋈, Frances Williamson MBBS (Hons), FACEM, PGDipClinUS, Michelle J. Bauer BSc (micro) ... See all authors ∨

First published: 12 June 2023 | https://doi.org/10.1002/jum.16286



# Thank you!

